featured
First-Line Talazoparib With Enzalutamide for HRR-Deficient Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Nat. Med. 2023 Dec 04;[EPub Ahead of Print], K Fizazi, AA Azad, N Matsubara, J Carles, AP Fay, U De Giorgi, JY Joung, PCC Fong, E Voog, RJ Jones, ND Shore, C Dunshee, S Zschäbitz, J Oldenburg, D Ye, X Lin, CG Healy, N Di Santo, AD Laird, F Zohren, N AgarwalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.